Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay

The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. Osimertinib is now also proposed as...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancers (Basel)
Huvudupphovsmän: Fresnais, Margaux, Roth, André, Foerster, Kathrin I., Jäger, Dirk, Pfister, Stefan M., Haefeli, Walter E., Burhenne, Jürgen, Longuespée, Rémi
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409122/
https://ncbi.nlm.nih.gov/pubmed/32674434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071897
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk